Quarterly report · Q2
4626.TEDINET S100PGNK
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥52.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥98.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥198.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥189.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥184.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥103.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥93.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥85.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥57.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥51.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥54.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥18.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥133.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.13 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.84 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥63.83 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥10.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥52.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥48.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 11234000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1998 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 5833000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1037 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 5773000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.1027 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 3342000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0594 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 3095000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0550 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 2232000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0397 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1490000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0265 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1193000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0212 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 1077000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0192 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 804000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0143 | |
| Number of shares held | CurrentQuarterInstant | 36075000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.6416 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2082600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1261 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 56065000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 560650 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 37901 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 58185501 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 561911 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1956500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | 126100 | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 2082600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0358 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 1956500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | 126100 | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 2082600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0358 | |
| Cash and deposits | Prior1YearInstant | 51557000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 57278000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 27558000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 28329000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 8096000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 8438000000 | JPY |
| Work in process | Prior1YearInstant | 1573000000 | JPY |
| Work in process | CurrentQuarterInstant | 1473000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 6714000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |